Haleon PLC Sponsored ADR (NYSE:HLN) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Haleon PLC Sponsored ADR (NYSE:HLN) have been assigned an average recommendation of “Moderate Buy” from the ten analysts that are covering the company, Marketbeat reports. Six investment analysts have rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company. The average 1-year price target among brokers that have covered the stock in the last year is $12.3250.

Several research firms have recently weighed in on HLN. Wall Street Zen cut Haleon from a “buy” rating to a “hold” rating in a report on Saturday, July 12th. Weiss Ratings restated a “hold (c)” rating on shares of Haleon in a report on Wednesday, October 8th. Barclays cut Haleon from an “overweight” rating to an “equal weight” rating in a report on Tuesday, September 16th. Finally, The Goldman Sachs Group upgraded Haleon from a “neutral” rating to a “buy” rating in a report on Wednesday, September 10th.

Haleon Stock Performance

NYSE:HLN opened at $9.48 on Monday. The stock has a market cap of $42.22 billion, a P/E ratio of 24.31, a price-to-earnings-growth ratio of 2.77 and a beta of 0.20. The company has a current ratio of 0.87, a quick ratio of 0.63 and a debt-to-equity ratio of 0.48. The stock’s 50-day moving average is $9.41 and its 200-day moving average is $9.99. Haleon has a 1-year low of $8.71 and a 1-year high of $11.42.

Haleon Increases Dividend

The business also recently disclosed a semi-annual dividend, which was paid on Thursday, September 18th. Investors of record on Friday, August 15th were paid a $0.0555 dividend. This is an increase from Haleon’s previous semi-annual dividend of $0.05. This represents a dividend yield of 190.0%. The ex-dividend date of this dividend was Friday, August 15th. Haleon’s payout ratio is presently 28.21%.

Hedge Funds Weigh In On Haleon

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Ethic Inc. lifted its stake in shares of Haleon by 4.5% in the third quarter. Ethic Inc. now owns 94,949 shares of the company’s stock worth $852,000 after acquiring an additional 4,056 shares during the period. Archford Capital Strategies LLC acquired a new position in shares of Haleon in the third quarter worth approximately $2,149,000. Highland Capital Management LLC lifted its stake in shares of Haleon by 10.7% in the third quarter. Highland Capital Management LLC now owns 27,305 shares of the company’s stock worth $245,000 after acquiring an additional 2,650 shares during the period. Blue Trust Inc. lifted its stake in shares of Haleon by 5.6% in the third quarter. Blue Trust Inc. now owns 55,000 shares of the company’s stock worth $493,000 after acquiring an additional 2,904 shares during the period. Finally, Founders Financial Securities LLC lifted its stake in shares of Haleon by 27.7% in the third quarter. Founders Financial Securities LLC now owns 209,432 shares of the company’s stock worth $1,879,000 after acquiring an additional 45,378 shares during the period. 6.67% of the stock is owned by institutional investors and hedge funds.

Haleon Company Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.